Trinity Biotech (TRIB) announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance ...

The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

DUBLIN, Ireland - Trinity Biotech plc (NASDAQ:TRIB), a leading provider of diagnostic solutions for the healthcare industry, ...

Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

Shares of Trinity Biotech climbed after the company released what it called compelling results from a study of its next-generation continuous glucose monitoring system, a device used for diabetes ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity ...

DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...